Liquidmetal® Technologies, Inc. formally introduced Nomad Sales as the Company‘s sales representative firm in the Midwest region of the US. Nomad Sales will be promoting Liquidmetal amorphous alloys for commercial markets such as aerospace, medical and industrial products. Liquidmetal® Technologies has also engaged Liolios Group to lead a new investor relations and financial communications program.
http://www.liquidmetal.com
MagForce AG (MF6.FSE) announced additions to the management board and further measures to enforce commercialization of NanoTherm® therapy. Thus, focussing on establishing the NanoTherm® therapy in the oncology market as well as on its commercialization for near-term value generation. In the short to mid term, MagForce will dedicate its financial resources to the post marketing trial in glioblastoma, which is expected to start in early 2013 and is supposed to make a significant contribution to its strategic set up. Simultaneously, the Company will also focus on the commercialization of its NanoTherm® therapy with its distribution partners including DELRUS and TekGrup, development partners such as the Mayo Clinic for gastrointestinal cancer and the Department of Urology at Duesseldorf University for prostate cancer, as well as the production of nanoparticles.
In line with this strategy, the Company’s core functions, including clinical and business development, medical affairs plus legal & IP will be concentrated at the MagForce site in Munich where these teams are already located. Production of nanoparticles, NanoActivators™, software engineering as well as the finance department will remain at the Company’s registered office in Berlin. Moreover, MagForce announced the financial results for the first half of the 2012 fiscal year, ending June 30, 2012. In the first half of the year, MagForce was able to successfully finalize distribution partnerships with DELRUS (Russia) and Tek Grup (Turkey), as well as a development partnership with the Mayo Clinic (USA). During the reporting period, the company recorded a loss of EUR3.6 million/USD4.65 million (prior year period: EUR4.6 million/USD5.94 million).
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93